Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/850 mg - sitagliptinhydrokloridmonohydrat 56,69 mg aktiv substans; metforminhydroklorid 850 mg aktiv substans; natriumlaurilsulfat hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ögonsjukdomar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; polysorbat 80 hjälpämne; dimetylfumarat 120 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - dimetylfumarat - enterokapsel, hård - 240 mg - polysorbat 80 hjälpämne; propylenglykol hjälpämne; dimetylfumarat 240 mg aktiv substans